We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a ...

Truist has recently raised Sangamo Therapeutics Inc (SGMO) stock to Buy rating, as announced on December 13, 2024, according to Finviz. Earlier, on December 10, 2024, H.C. Wainwright had reiterated ...

NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.

NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a biotechnology company specializing in genomic medicine and gene therapies, stands at a critical juncture as it navigates a complex landscape of clinical ...

Law Offices of Howard G. Smith announces an investigation on behalf of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) investor ...

NEW YORK, Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ: SGMO). Such investors are ...

NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) ...